|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Svelte Medical Systems, Inc. Announces Treatment of First Patient in the ACES Effectiveness Study
12/20/2012 9:06:49 AM
NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced treatment of the first patient in the ACES (Acrobat Coronary stent system effectiveness European Study) clinical trial by Victor Legrand, MD, PhD at CHU Liege in Liege, Belgium. ACES is a randomized, controlled study designed to demonstrate the positive clinical benefit and impact on resource utilization of the Svelte Acrobat Integrated Delivery System (IDSTM) compared with conventional coronary stent devices in patients with lesions eligible for direct stenting. Up to 300 patients will be enrolled in the study at 12 sites in France, Belgium and Spain. A fixed-wire based system, the Svelte coronary stent IDS is low profile and highly flexible, navigating through the vasculature similar to a traditional guidewire, allowing physicians to ‘direct-stent’ coronary artery lesions and eliminate several steps in their current stenting procedures. Non-randomized data presented at medical symposia earlier this year suggest the Svelte IDS significantly reduces radiation exposure, contrast use, adjunctive interventional product use and overall procedure time when compared with conventional stent systems.
|
|
|
|
|
|
|
|
|
|
|